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ative failure, complications and patient non-compliance.
A population model was applied to follow to the life-long
impact of individuals receiving cataract surgery. Costing
estimates are based on primary data collection in 14 epi-
demiological sub-regions by regional costing teams and
literature review, and were estimated for different cover-
age levels using non-linear cost functions. RESULTS:
Intra- and extra-capsular cataract surgery are cost-
effective ways to reduce the impact of cataract-blindness.
Extra-capsular cataract surgery is more cost-effective
than intra-capsular surgery in all regions considered, and
higher coverage levels are always more cost-effective than
lower coverage levels. Extra-capsular cataract surgery at
a 95% coverage level would avert over 3.8 million dis-
ability adjusted life years per year globally. The cost-
effectiveness ranges from I$69 per DALY in SearD (South
East Asian Region with high child and adult mortality)
to I$2341 per DALY in WprA (Western Paciﬁc Region
with low child and adult mortality). CONCLUSIONS: In
cataract surgery, extra-capsular surgery at high coverage
level is the most cost-effective way for restoring eyesight.
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OBJECTIVES: As no Canadian data exist yet, the objec-
tive of the study is to determine the burden of illness of
patients suffering from eczema in Canada. The resource
use, direct costs, indirect costs, demographics and other
factors affected by eczema were measured over a 1-year
period. METHODS: Patients were recruited through
Community Pharmacists in Canada and were asked to ﬁll
out a four-page survey. Information about gender, age,
marital status, employment status, income, healthcare
practitioner visits, other medical services visits, hospital-
ization, absenteeism at work/school, over-the-counter
(OTC) treatment, household expenses, sleep distur-
bances, severity and duration of the disease, number of
ﬂares and length of each ﬂare and type of insurance cov-
erage were collected. Costs were attached to the different
variables to calculate the burden of illness of eczema for
the whole cohort but the group was also divided by
disease severity. RESULTS: Over 100 patients were
recruited and more than 70 patients have returned the
survey to this point. Each patient has visited a physician
due to his/her eczema at least once in the last 12 months.
The two variables that have had the most impact on the
cost of the disease are the consumption of OTC medica-
tions and the extra household expenses incurred by the
patient. As expected, the burden increases with the sever-
ity of the disease. Nobody was hospitalised due to their
eczema. CONCLUSIONS: Taken individually, the eco-
nomic burden of eczema is not exceptionally high but
given the prevalence of the disease it represents a high
burden for the society. The results are within the range of
what has been published until now. Prescription costs
were not measured directly in this survey and thus the
results are most likely underestimated.
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OBJECTIVES: To investigate the validity of the 39-item
National Eye Institute Visual Function Questionnaire
(NEI-VFQ-39) at baseline in German patients with 
age-related macular generation (AMD). METHODS:
Ongoing prospective observational study in which 137
patients attended a clinic in Germany. Patients belonged
to one of 3 severity classes: 1) early AMD in both eyes (n
= 25); 2) late-stage AMD in one eye and early-stage AMD
in the other eye (n = 71); and 3) late-stage AMD in both
eyes (n = 41). Correlations of baseline scores were calcu-
lated between NEI-VFQ-39 and visual acuity. Baseline
mean scores on the NEI-VFQ-39 were compared for dif-
ferent AMD severity using linear regression adjusting for
gender, age, education, and smoking. RESULTS: Scores
on visual acuity correlated moderately, as expected, with
NEI-VFQ-39 domain scores on General Vision (r = 0.48),
Near Activities (r = 0.52), Distant Activities (r = 0.46),
and Peripheral Vision (r = 0.44). As expected, visual
acuity correlated modestly though meaningfully with
Social Functioning (r = 0.31), Mental Health (r = 0.31),
Role Difﬁculties (r = 0.36), Dependency (r = 0.38),
Driving (r = 0.34), and Color Vision (r = 0.30); visual
acuity showed little or no correlation with General Health
(r = 0.13) and Ocular Pain (r = -0.09). Signiﬁcant differ-
ences (p < 0.01) in mean scores among severity levels of
AMD were observed for all NEI-VFQ-39 domains except
for domains on Driving, General Health, and Ocular
Pain. CONCLUSIONS: The German version of the NEI-
VFQ-39 exhibits baseline validity as a measure of func-
tional impairment in patients with AMD.
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OBJECTIVES: To assess patient satisfaction and eco-
nomic implications associated with a new formulation of
